Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24070Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:37:43Z | - |
| dc.date.available | 2015-11-24T19:37:43Z | - |
| dc.identifier.issn | 1744-7682 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24070 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Antibodies, Monoclonal/pharmacology/*therapeutic use | en |
| dc.subject | Antibodies, Monoclonal, Humanized | en |
| dc.subject | Antirheumatic Agents/pharmacology/therapeutic use | en |
| dc.subject | Arthritis, Rheumatoid/immunology/metabolism/*therapy | en |
| dc.subject | Humans | en |
| dc.subject | Tumor Necrosis Factor-alpha/antagonists & inhibitors/immunology | en |
| dc.title | Adalimumab for rheumatoid arthritis | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1517/14712598.6.12.1349 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17223742 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14712598.6.12.1349 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | In the last few years significant advances have been made in our understanding of the molecular mechanisms underlying rheumatoid arthritis pathogenesis. Pro-inflammatory cytokines, such as TNF-alpha, play a pivotal role in its pathogenesis. Anti-TNF-alpha biological agents are considered a major advance in the treatment of rheumatoid arthritis. Adalimumab is a fully human monoclonal antibody that binds specifically to TNF-alpha, thereby neutralising its activity. It had significant efficacy in well-designed, placebo-controlled trials in patients suffering from rheumatoid arthritis, both as monotherapy and in combination with various disease-modifying antirheumatic drugs, including methotrexate. Adalimumab was generally well tolerated during both concomitant therapy with methotrexate or standard antirheumatic therapy and monotherapy. In addition, the radiographic progression of structural joint damage was significantly inhibited by adalimumab and improved quality of life. This review summarises the recent available data. | en |
| heal.journalName | Expert Opin Biol Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
